My Community - Clinical Information


Publications

The following are published, peer-reviewed papers on the latest research and clinical studies related to Cerezyme® and Gaucher disease. Reading the abstracts of these papers will help keep you informed and up-to-date on news and advances in this medical field.


Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease.
Maas M, Hangartner T, Mariani G, Skeletal Radiol. 2008 Mar;37(3):185-8.
http://www.ncbi.nlm.nih.gov/pubmed/18094966
Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
Drelichman G, Ponce E, Basack N, et al. J Pediatr. 2007 Aug;151(2):197-201.
http://www.ncbi.nlm.nih.gov/pubmed/17643778
Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ, Kacena KA, Kaplan P, et al. J Bone Miner Res. 2007;22:119-126.
http://www.ncbi.nlm.nih.gov/pubmed/17032149
Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.
Weinreb N, Barranger J, Packman S, et al. Clin Genet. 2007;71:576-588.
http://www.ncbi.nlm.nih.gov/pubmed/17539908
The long-term international safety experience of imiglucerase therapy for Gaucher disease
Starzyk K, Richards S, Yee J, et al. Mol Genet Metab. 2007;90:157-163.
http://www.ncbi.nlm.nih.gov/pubmed/17079176
The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
Kaplan P, Andersson HC, Kacena KA, et al. Arch Pediatr Adolesc Med. 2006;160:603-608.
http://www.ncbi.nlm.nih.gov/pubmed/16754822
Individualization of long-term enzyme replacement therapy for Gaucher disease.
Andersson HC, Charrow J, Kaplan P, et al. Genet Med. 2005 Feb;7(2):105-10.
http://www.ncbi.nlm.nih.gov/pubmed/15714077
Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease:
consensus recommendations. Charrow J, Andersson HC, Kaplan P, et al. J Pediatr. 2004 Jan;144(1):112-20. Review.
http://www.ncbi.nlm.nih.gov/pubmed/14722528
The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J, Dulisse B, Grabowski GA, et al. Clin Genet. 2007;71:205-211.
http://www.ncbi.nlm.nih.gov/pubmed/17309642
Therapeutic goals in the treatment of Gaucher disease.
Pastores GM, Weinreb NJ, Aerts H, et al. Semin Hematol. 2004;41(Suppl 5):4-14.
http://www.ncbi.nlm.nih.gov/pubmed/15468045
The International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients.
Weinreb NJ, Aggio MC, Andersson HC, et al. Semin Hematol. 2004;41(Suppl 5):15-22.
http://www.ncbi.nlm.nih.gov/pubmed/15468046

Read more clinical information about Gaucher disease in Sanofi Genzyme Gaucher Research